Sorry, you need to enable JavaScript to visit this website.

    Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers




    Pfizer Oncology will host a journalist briefing at the American
      Society of Clinical Oncology (ASCO) Annual Meeting on Sunday,
      June 1, 2008, highlighting key data presentations from a variety
      of compounds in several difficult-to-treat tumor types,
      including renal cell carcinoma and non-small cell lung cancer.
      Leading oncology physicians and researchers will present study
      results and offer their professional perspective.


    Robert Figlin, M.D., F.A.C.P., City of Hope

      Abstract #5024: "Overall survival with sunitinib versus
      interferon (IFN)-alfa as first-line treatment of metastatic
      renal cell carcinoma (mRCC)"

    Antonio Gualberto, M.D., Ph.D., Pfizer Global Research and



      Abstract #10501: "Safety, pharmacokinetics and preliminary
      activity of the anti-IGF-1R antibody CP-751,871 in
      sarcoma patients"

    Daniel Karp, M.D., M.D. Anderson Cancer Center

      Abstract #8000: "Characterization of NSCLC patients responding
      to anti-IGF-1R therapy"

    Pasi A. Janne, M.D., Ph.D., Dana-Farber Cancer Institute

      Abstract #8027, Poster #8: "Preliminary activity and safety
      results from a phase I clinical trial of PF-00299804, an
      irreversible pan-HER inhibitor, in patients (pts) with NSCLC"

    John H. Sampson, M.D., Ph.D., Duke University Medical Center

      Abstract #2061: "Effect of EGFRvIII-targeted vaccine (CDX-110)
      on immune response and TTP when given with simultaneous standard
      and continuous temozolomide in patients with GBM"


    Sunday, June 1, 2008 at 6:00 PM (CT)



    Westin River North - Grand Ballroom A&B
      320 N. Dearborn Avenue
      Chicago, IL 60610

    (312) 744-1900

    Rx Mosaic Health
    Jacqueline Karis
    [email protected]


    Product Pipeline

    Learn about specific ways our research is leading to medicines and vaccines that will benefit patients around the world.

    Corporate Fact Sheet

    For more than 170 years, Pfizer has worked to make a difference for all who rely on us.

    Coronavirus Resources

    Learn about SARS-CoV-2, the coronavirus that causes COVID-19, what you can do to stay safe and prevent the spread, and our scientific efforts to help bring an end to the current global health crisis.

    Pfizer Logo

    Our logo is shorthand for everything Pfizer represents: an image that is instantly identifiable to our colleagues, patients, the external scientific community, and the public.

    Executive Leadership

    Meet the executive leadership team, our senior-most leadership and decision-making management body who focus on major financial, strategic, and operational decisions for the entire company.